ReviewPediatric discovery2023
Advances of SIRT4 in cancer metabolism and therapy.
Review in Pediatric discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Sirtuins as Therapeutic Targets for Treating Cancer, Metabolic Diseases, and Neurodegenerative Diseases.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- The Role of the Sirtuin Family Histone Deacetylases in Acute Myeloid Leukemia-A Promising Road Ahead.Cancers · 2025Review
- Advances of SIRT4 in cancer metabolism and therapy.Pediatric discovery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Sirtuins family consists of SIRT1-SIRT7, which belong to class III of the histone deacetylases, a family of highly conserved NAD (nicotinamide adenine dinucleotide)-dependent enzymes expressed in the nucleus, cytoplasm, and mitochondria. In addition to having ADP-ribosyltransferase, NAD+-dependent deacetylase, lipoamide, and long-chain deacetylase activities, it can also regulate the function of substrate proteins through ADP-ribosylation, diacylation, and long-chain deacylation. These enzyme activities also confer many critical biological functions on SIRT4, making SIRT4 involved in many mitochondrial energy metabolic processes, such as promoting insulin secretion, participating in the glycolytic process in concert with glycolysis inhibitors, inhibiting glutamate dehydrogenase from regulating glutamine metabolism, and participating in reactions such as DNA damage. Because SIRT4 has such diverse functions, it plays a role in the metabolism and treatment of tumors. Here, we review the progress of SIRT4 research in tumor metabolism and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.